The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes

Leukemia Research

Volumn 32, Issue 2, 2008, Pages 211-213

  Lorand Metze, I ^a   Califani, S M V ^a   Ribeiro, E ^a   Lima, C S P ^a   Metze, K ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Cell maturation; Flow cytometry; Myelodysplastic syndromes; Phenotypic aberrations; Prognosis

Indexed keywords

CD45 ANTIGEN; MICROSOMAL AMINOPEPTIDASE;

ARTICLE; CELL MATURATION; COMPUTER PROGRAM; HUMAN; MYELODYSPLASTIC SYNDROME; NEUTROPHIL; PHENOTYPE; PRIORITY JOURNAL; REFRACTORY ANEMIA; RISK FACTOR; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD13; ANTIGENS, CD34; ANTIGENS, CD45; BONE MARROW CELLS; CELL LINEAGE; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOPHENOTYPING; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHENOTYPE; PLATELET COUNT; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 38949134156     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.06.014     Document Type: Article

References (9)

1. Lorand-Metze I., Ribeiro E., Lima C.S.P., Batista L.S., and Metze K. Detection of hematopoietic maturation abnormalities by flow cytometry in myelodysplastic syndromes and its utility for the differential diagnosis with non-clonal disorders. Leuk Res 31 (2007) 147-155
2. Orfao A., Ortuño F., De Santiago M., Lopez A., and San Miguel J.F. Immunophenotyping of acute leukemias and myelodysplastic syndromes. Cytometry 58 (2004) 62-71
3. Wells D.A., Benesch M., Loken M.R., Vallejo C., Myerson D., Leisernring W.M., et al. Myeloid and monocytic dispoiesis as determinated by flow cytometry scoring in myelodysplastic syndromes correlates with the IPSS and with outcome after hemopoietic stem cell transplantation. Blood 102 (2003) 394-405
4. Ribeiro E., Lima C.S.P., Metze K., and Lorand-Metze I. Flow cytometry analysis of the expression of Fas/Fas-L in bone marrow CD34+ cells in myelodysplastic syndromes. Relation to disease progression. Leuk Lymphoma 45 (2004) 309-313
5. Pirrucello S.J., Young K.H., and Aoun P. Myeloblast phenotypic changes in myelodysplasia. Am J Clin Pathol 125 (2006) 884-894
6. Lorand-Metze L., Pinheiro M.P., Ribeiro E., Paula E.V., and Metze K. Factors influencing survival in myelodysplastic syndromes in a brazilian population: comparison of FAB and WHO classifications. Leuk Res 28 (2004) 587-594
7. Valent P, Horny H-P, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: consensus statements and report from a working conference. Leuk Res 2007, e.published.
8. Ogata K., Kishikawa Y., Satoh C., Tamura H., Dan K., and Hayashi A. Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 108 (2006) 1037-1044
9. Malcovati L., Germing U., Kuendgen A., Della Porta M.G., Invernizzi R., Giagounidis A., et al. A WHO classification-based prognostic scoring system (WPSS) for predicting survival in myelodysplastic syndromes. Blood 106 (2005) 232a-233a